Bangkok Genomics Innovation Public Company Limited

As of June 30, 2026, Bangkok Genomics Innovation Public Company Limited carries a market capitalization of 1.22B, placing it among publicly traded companies globally. Its enterprise value stands at 1.01B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Bangkok Genomics Innovation Public Company Limited's next confirmed earnings release is scheduled for November 11, 2026.

As of June 30, 2026, Bangkok Genomics Innovation Public Company Limited has 600.00M shares outstanding.

As of June 30, 2026, Bangkok Genomics Innovation Public Company Limited trades at a trailing price-to-earnings ratio of 17.97. The price-to-sales ratio is 2.68, and the price-to-book ratio stands at 2.10.

As of June 30, 2026, Bangkok Genomics Innovation Public Company Limited trades at an EV/EBITDA multiple of 10.13 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.22 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 13.14 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 1.01B versus a market cap of 1.22B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Bangkok Genomics Innovation Public Company Limited maintains a current ratio of 4.45, meaning it holds 4.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 3.25, indicating elevated leverage, while an interest coverage ratio of 72.31 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Bangkok Genomics Innovation Public Company Limited posted a return on equity (ROE) of 12.07, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 12.33 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 10.04, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 11.82, useful for judging operating efficiency across full business cycles. The company generates approximately 6.71M in revenue per employee across its workforce of 68.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 5.49 indicates how many times Bangkok Genomics Innovation Public Company Limited sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Bangkok Genomics Innovation Public Company Limited recorded 4.56M in income tax expense. That works out to an effective tax rate of 6.28, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 72.59M, leaving 68.12M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Bangkok Genomics Innovation Public Company Limited's stock has gained approximately 48.75% over the past 52 weeks. The 50-day moving average sits at 2.31, while the 200-day moving average is 1.77.

Over the twelve months ended June 30, 2026, Bangkok Genomics Innovation Public Company Limited generated 456.31M in revenue and converted that into 68.12M in net income, yielding earnings per share of 0.11. EBITDA reached 100.07M, while operating income came in at 74.19M.

As of June 30, 2026, Bangkok Genomics Innovation Public Company Limited holds 232.95M in cash and equivalents against 19.08M in total debt, resulting in a net debt position of -132.91M. Total book value stands at 583.55M, with working capital of 468.02M providing operational flexibility.

Bangkok Genomics Innovation Public Company Limited produced -54.58M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -42.45M in capital expenditures, free cash flow totaled -97.02M - equivalent to -0.16 per share.

Over the twelve months ended June 30, 2026, Bangkok Genomics Innovation Public Company Limited posted a gross margin of 40.21, reflecting its pricing power and cost economics. The operating margin of 16.26 and net profit margin of 14.93 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Bangkok Genomics Innovation Public Company Limited paid dividends of 0.00 per share. The dividend payout ratio of 0.01 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -7.93: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 4.90, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Bangkok Genomics Innovation Public Company Limited shareholders.

As of June 30, 2026, Bangkok Genomics Innovation Public Company Limited has an Altman Z-Score of 6.67, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.